Another novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, tirzepatide, not only reduces body weight but also improves the metabolite profile in patients with T2D (38, 39). Here, GLP1R is linked to type 2 diabetes mellitus.